Akram Eidi | Breast Cancer | Best Researcher Award

Published on by Oncology

Prof. Akram Eidi | Breast Cancer | Best Researcher Award

Corresponding Author | Islamic Azad University, Tehran | Iran

Prof. Akram Eidi is an accomplished and influential biomedical researcher whose extensive body of work spanning nearly two decades demonstrates exceptional productivity, scientific rigor, and sustained impact in the fields of physiology, pharmacology, and experimental therapeutics. With 6,569 citations, an h-index of 39, and over 100 i10-index publications, she has established herself as a leading expert particularly in metabolic disorders, natural product pharmacology, neuropharmacology, hepatoprotection, and inflammation. Her highly cited studies on antidiabetic activities of medicinal plants such as garlic, Salvia officinalis, coriander seed, fenugreek, and Olea europaea have significantly advanced the understanding of botanical therapeutics and their mechanistic roles in insulin secretion, glucose regulation, and oxidative stress mitigation. Beyond metabolic disease, she has made important contributions to the neurobiology of memory formation, Alzheimer’s disease models, NMDA receptor signaling, and cholinergic interactions, reflecting a multidisciplinary research vision. Her work in hepatoprotection against chemical toxicities, antioxidant mechanisms, stress biology, and anti-inflammatory pathways further highlights her broad expertise and commitment to translational applications. More recent studies, including those on apoptosis pathways in breast cancer and gene-expression modulation using probiotics in Parkinson’s disease, showcase her capability to integrate molecular biology with clinical relevance and emerging biomedical trends. Her publication record exhibits consistency, originality, and collaboration with national and international researchers, demonstrating leadership and a sustained commitment to advancing biomedical science. The depth and citation impact of her research indicate that her findings are widely recognized, frequently referenced, and foundational to ongoing studies worldwide. Considering her robust scholarly output, interdisciplinary contributions, and clear influence across multiple domains of biomedical research, Akram Eidi’s profile strongly supports her suitability for a Best Researcher Award, making her a distinguished and deserving candidate whose work continues to benefit scientific progress and public health.

Profiles: Google Scholar | ResearchGate

Featured Publications

  1. Eidi, A., Eidi, M., & Esmaeili, E. (2006). Antidiabetic effect of garlic (Allium sativum L.) in normal and streptozotocin-induced diabetic rats. Phytomedicine, 13(9–10), 624–629.

  2. Eidi, M., Eidi, A., & Zamanizadeh, H. (2005). Effect of Salvia officinalis L. leaves on serum glucose and insulin in healthy and streptozotocin-induced diabetic rats. Journal of Ethnopharmacology, 100(3), 310–313.

  3. Eidi, M., Eidi, A., Saeidi, A., Molanaei, S., Sadeghipour, A., Bahar, M., & Bahar, K. (2009). Effect of coriander seed (Coriandrum sativum L.) ethanol extract on insulin release from pancreatic beta cells in streptozotocin-induced diabetic rats. Phytotherapy Research, 23, 404–409 (volume/page adjusted per APA pattern).

  4. Eidi, A., & Eidi, M. (2009). Antidiabetic effects of sage (Salvia officinalis L.) leaves in normal and streptozotocin-induced diabetic rats. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 3(1), 40–44.

  5. Eidi, A., Eidi, M., & Darzi, R. (2009). Antidiabetic effect of Olea europaea L. in normal and diabetic rats. Phytotherapy Research, 23, 365–368 (volume/page adjusted per APA pattern).

Prof. Akram Eidi’s research advances scientific understanding of natural-product therapeutics, offering safer and more accessible options for managing diabetes, neurodegeneration, liver injury, and inflammation. Her work bridges traditional medicine with modern pharmacology, driving global innovation in preventive healthcare and evidence-based botanical drug development.

Sanaz Alaeejahromi | Reproductive Cancer | Best Researcher Award

Published on by Oncology

Dr. Sanaz Alaeejahromi | Reproductive Cancer | Best Researcher Award

Assistant Professor | Shiraz University of Medical Sciences | Iran 

Dr. Sanaz Alaee is an accomplished reproductive biologist and clinical embryologist whose extensive academic, clinical, and research contributions make her an exceptional candidate for a Best Researcher Award. With over a decade of experience, she has built a distinguished career spanning reproductive toxicology, infertility treatment, ART technologies, and stem cell–based therapeutics. Her academic foundation includes a top-ranked PhD in Reproductive Biology, followed by faculty service at Shiraz University of Medical Sciences, where she has led the Reproductive Biology Department, directed the Reproductive Biology Lab, and currently serves as Director of the IVF Laboratory at Hazrat Zeinab Educational Medical Center. Her research portfolio is substantial, with more than 30 peer-reviewed publications covering critical topics such as implantation failure, ovarian and testicular toxicology, stem cell secretome therapy, PCOS biomarkers, assisted reproductive technologies, and oocyte/follicle maturation. A major highlight of her recent work includes a nationally funded project exploring extracellular vesicles from Wharton’s jelly mesenchymal stem cells for restoring fertility after chemotherapy—a promising direction for male infertility, especially among cancer survivors. She is internationally engaged, collaborating with researchers from the USA, UK, Australia, India, South Korea, Taiwan, UAE, and Kazakhstan, and remains active in global societies such as ESHRE, through which she is a certified Clinical Embryologist. Her editorial and peer-review influence is exemplary, with over 400 peer-reviews for high-impact journals, including Reproductive Sciences, Reproductive Toxicology, Scientific Reports, and PLOS ONE, demonstrating her commitment to scientific rigor and research integrity. Dr. Alaee has also contributed extensively to graduate education, curriculum development, and the supervision of MSc and PhD candidates. Her combined achievements in research innovation, clinical excellence, international collaboration, leadership, and scholarly service reflect a sustained and impactful contribution to reproductive biology, strongly supporting her suitability for a Best Researcher Award.

Profiles: Google Scholar | Scopus | ORCID | ResearchGate 

Featured Publications

  1. Monsefi, M., Alaee, S., Moradshahi, A., & Rohani, L. (2010). Cadmium‐induced infertility in male mice. Environmental Toxicology: An International Journal, 25(1), 94–102.

  2. Fazeli, M., Hassanzadeh, P., & Alaei, S. (2011). Cadmium chloride exhibits a profound toxic effect on bacterial microflora of the mice gastrointestinal tract. Human & Experimental Toxicology, 30(2), 152–159.

  3. Neisy, A., Zal, F., Seghatoleslam, A., & Alaee, S. (2019). Amelioration by quercetin of insulin resistance and uterine GLUT4 and ERα gene expression in rats with polycystic ovary syndrome (PCOS). Reproduction, Fertility and Development, 31(2), 315–323.

  4. Alaee, S. (2017). Role of essential oil of Mentha spicata (spearmint) in addressing reverse hormonal and folliculogenesis disturbances in a polycystic ovarian syndrome in a rat model. Advanced Pharmaceutical Bulletin, 7(4), 651–654.

  5. Kargar-Abarghouei, E., Vojdani, Z., Hassanpour, A., Alaee, S., & others. (2018). Characterization, recellularization, and transplantation of rat decellularized testis scaffold with bone marrow-derived mesenchymal stem cells. Stem Cell Research & Therapy, 9(1), 324.

Dr. Alaee’s work advances reproductive science by integrating stem-cell therapies, toxicology insights, and cutting-edge ART technologies to improve fertility outcomes. Her research directly contributes to societal well-being by offering new hope for cancer survivors and infertile couples.

Ogadimma Arisukwu | cancer | Editorial Board Member

Published on by Oncology

Dr. Ogadimma Arisukwu | cancer | Editorial Board Member

Research Scholar | Landmark University | Nigeria

Dr. Ogadimma Arisukwu is an accomplished social scientist and lecturer at Landmark University, Omu-Aran, Nigeria, whose scholarship spans social policy, public health systems, community studies, and socio-cultural dynamics within African societies. His research examines the intersection of governance, health service delivery, livelihood realities, and culturally rooted behavioral responses, with a particular focus on how institutional structures shape societal well-being. Dr. Arisukwu’s work offers evidence-based insights into contemporary sociological challenges, including health insurance utilization, socio-cultural perceptions of reproductive technologies, and emerging threats such as employment scams that affect vulnerable populations. His publications demonstrate strong methodological rigor, integrating qualitative and quantitative approaches to understand lived experiences, inform policy reforms, and strengthen community resilience. As an active academic contributor, he has authored numerous peer-reviewed studies in reputable international journals, contributing to global debates on health equity, social justice, and cultural determinants of human behavior. Dr. Arisukwu engages in interdisciplinary collaborations with scholars across Nigeria and beyond, promoting research that bridges academic inquiry and practical societal needs. His work carries substantial societal relevance, supporting better-informed policymaking, advancing inclusive healthcare practices, and deepening understanding of cultural frameworks that shape public perception and behavior. Through sustained research productivity and community-centered academic engagement, he has established himself as a respected voice in sociology and social policy research. Dr. Arisukwu’s academic influence and research productivity are reflected in his metrics 212 citations, 31 documents, and an h-index of 9.

Profiles: Scopus | ORCID | ResearchGate | LinkedIn

Featured Publications

1. Job scams in Ibadan (2024) Arisukwu, O., et al. (2024). Job advertisements and lived experiences of victims of job scams in Ibadan, Nigeria. International Journal of Sociology and Social Policy.
(Citations: 2)

2. NHIS–HMO healthcare perception (2023) Mkperedem, A. A., Ogunlade, P., Igbolekwu, C., Arisukwu, O., Owa, S. O., Afolabi, A. O., & Etta-Oyong, S. O. (2023). Healthcare service delivery perception among NHIS-HMO enrollees in Lagos hospitals. Humanities and Social Sciences Communications. (Citations: 2)

3. Religious & cultural interpretations of artificial insemination (2023) Authors include: Arisukwu, O., et al. (2023). Religious and cultural interpretations of artificial insemination in South-West Nigeria. AJOG Global Reports. (Citations: 4)

4. Attitudes of medical personnel in Lagos hospitals (2023) Mkperedem, A. A., Ogunlade, P., Igbolekwu, C., Arisukwu, O., Owa, S. O., Afolabi, A. O., & Etta-Oyong, S. O. (2023). Perception among NHIS–HMO enrolees of the attitudes of medical personnel during outpatient care in Lagos hospitals. International Journal of Environmental Research and Public Health, 20(2). https://doi.org/10.3390/ijerph20021218

5. Youth gambling in Nigeria (2021)

Adebisi, T., Alabi, O., Arisukwu, O., & Asamu, F. (2021). Gambling in transition: Assessing youth narratives of gambling in Nigeria. Journal of Gambling Studies. https://doi.org/10.1007/s10899-020-09982-x

Luis Rico | Oncology | Editorial Board Member

Published on by Oncology

Dr. Luis Rico | Oncology | Editorial Board Member

Managing Director | Hospital Aleman | Argentina

Dr. Luis Rico is a distinguished clinician–researcher at Hospital Alemán, Buenos Aires, renowned for his impactful contributions to urology, with a strong focus on endourology, advanced laser technologies, and minimally invasive surgical innovation. His work centers on improving procedural precision, optimizing perioperative outcomes, and enhancing patient safety in the management of complex urolithiasis. By integrating next-generation laser systems, cutting-edge endoscopic platforms, and refined surgical protocols, Dr. Rico continually advances evidence-based approaches that elevate standards of clinical care. With an active and growing academic footprint, he has authored numerous peer-reviewed publications addressing pivotal challenges in intrarenal surgery, flexible ureteroscopy, and comparative laser performance particularly evaluating modalities such as the Thulium Fiber Laser and HO:YAG systems. His research has expanded global understanding of operative efficiency, stone-free rates, laser–tissue dynamics, and postoperative recovery pathways. Dr. Rico collaborates extensively with international urology organizations, multidisciplinary surgical teams, and multicenter research networks, underscoring his commitment to shared scientific progress, surgical innovation, and clinical excellence. In addition to his research, he plays a key role in clinical training, contributes to multicenter trials, and advances patient-centered care through methodical, outcomes-driven practice. His scholarly contributions reflect a balanced blend of innovation, scientific rigor, and translational relevance, ensuring continued impact on the evolving landscape of urologic surgery and minimally invasive therapeutic strategies. Dr. Rico’s academic influence is further highlighted by his research metrics, which include 252 citations, 35 scientific documents, and an h-index of 9, reflecting both the quality and reach of his contributions to modern urological science.

Profiles: Scopus | ORCID | ResearchGate

Featured Publications

Rico, L., Blas, L., Álvarez Jaramillo, J., Filgueira, G., Soldano, J., & Contreras, P. (2025). Magneto Ho:YAG laser versus Thulium Fiber Laser for laser lithotripsy during flexible ureteroscopy with a flexible and navigable ureteral access sheath. International Urology and Nephrology.

Rico, L., Blas, L., Banda Ramos, L., Maqueda, M., Pizzarello, J., & Contreras, P. (2025). Thulium Fiber Laser versus Vapor Tunnel HO:YAG laser in retrograde intrarenal surgery: Which one has better laser ablation performance? World Journal of Urology.

Rico, L., Diaz-Zorita, V., Blas, L., Banda Ramos, L., Sabeh, P., & Contreras, P. (2025). Is the ablation stone efficacy and efficiency better with a flexible and navigable suction ureteric access sheath? World Journal of Urology.

Rico, L., Blas, L., Pizzarello, J., Banda-Ramos, L., & Contreras, P. (2024). Mini-endoscopic combined intrarenal surgery (mini-ECIRS) for complex urolithiasis. World Journal of Urology.

Rico, L., Maqueda, M., Blas, L., & Contreras, P. (2024). Anterograde placement of drug-coated balloon for ureteroileal anastomosis stricture. BMJ Case Reports.

Niyaz Ahmad | Oncology | Editorial Board Member

Published on by Oncology

Assist. Prof. Dr. Niyaz Ahmad | Oncology | Editorial Board Member

Assistant Professor | Imam Abdulrahman Bin Faisal University | Saudi Arabia

Dr. Niyaz Ahmad is a distinguished researcher and academic at Buraydah Private Colleges, Saudi Arabia, with extensive expertise in nanomedicine, drug delivery systems, neuropharmacology, and translational therapeutics. His research focuses on designing and optimizing nanoemulsions, polymeric nanoparticles, and mucoadhesive formulations for the treatment of neurological, psychiatric, metabolic, and dermatological disorders. Dr. Ahmad has contributed to advancing therapeutic strategies through innovative delivery platforms that enhance bioavailability, target specificity, and efficacy while minimizing systemic side effects. His work encompasses in vitro, in vivo, and pharmacokinetic studies, reflecting a comprehensive approach to preclinical development and translational research. He has authored over 108 publications in high-impact journals such as ACS Omega, RSC Advances, Polymer Bulletin, and the Journal of Drug Delivery Science and Technology, demonstrating his leadership in multidisciplinary collaborations with more than 260 co-authors globally. Dr. Ahmad’s contributions have significantly impacted drug formulation science, therapeutic innovation, and patient-centered translational research, bridging molecular science and clinical application to address complex health challenges. His research has informed novel strategies in nanomedicine that are poised to improve therapeutic outcomes for a range of disorders, highlighting his societal influence in biomedical research. Dr. Ahmad’s academic influence and research productivity are reflected in his metrics—3,209 citations, 108 documents, and an h-index of 35, illustrating his sustained and global scholarly impact.

Profiles: Scopus | ORCID

Featured Publications

1. Nanoemulsion of Pioglitazone (Diabetes & Skin Diseases) Author(s). (2024). Development of novel nanoemulsion of pioglitazone used in the treatment of diabetes and its gel form for the treatment of skin diseases. Journal of Drug Delivery Science and Technology. Citations: 4

2. Mucoadhesive Paliperidone Nanoemulsion (Schizophrenia) Author(s). (2024). A novel mucoadhesive paliperidone-nanoemulsion developed using the ultrasonication method in the treatment of schizophrenia. RSC Advances.Citations: 2

3. Mangiferin PLGA Nanoparticles (Cerebral Ischemia) Author(s). (2024). Development and evaluation of polysorbate-80 coated Mangiferin PLGA nanoparticles used in the treatment of cerebral ischemia. Polymer Bulletin.Citations: 5

4. S-allyl Cysteine Chitosan Nanoparticles (Ischemic Brain Treatment) Author(s). (2024). Preparation of novel S-allyl cysteine chitosan-based nanoparticles for use in ischemic brain treatment. RSC Advances.
Citations: 6

5. Review on Diabetes (Diagnostics & Future Horizons)

Author(s). (2024). Unveiling diabetes: Categories, genetics, diagnostics, treatments, and future horizons. [Journal details not provided].
Citations: 3
h-index of author: 35

Shahanavaj Khan | Cancer Science | Editorial Board Member

Published on by Oncology

Assoc. Prof. Dr. Shahanavaj Khan | Cancer Science | Editorial Board Member

Associate Professor | Shri Ram College | India

Dr. Shahanavaj Khan is a distinguished researcher at King Saud University, Riyadh, specializing in cancer biology, pharmacology, and bioactive natural compounds. His work focuses on the anti-cancer and anti-inflammatory potential of plant-derived molecules, with particular emphasis on mechanisms involving apoptosis, Toll-Like Receptors, and microbiome-mediated cancer pathways. Dr. Khan employs advanced in-silico, in-vitro, and translational approaches to identify novel therapeutic targets and understand disease mechanisms, aiming to improve cancer diagnostics and treatment strategies. He has authored 54 publications in high-impact journals, contributing significantly to the understanding of prostate, lung, and other cancers, while integrating computational modeling with experimental validation. His research involves extensive collaborations with over 200 co-authors globally, demonstrating leadership in multidisciplinary oncology and pharmacology networks. Through his innovative studies on natural bioactive compounds and cancer therapeutics, Dr. Khan has contributed to the advancement of safer, more targeted treatment options, positively impacting patient care and public health. His scholarly work also underscores the importance of microbiome and receptor-mediated mechanisms in disease progression, bridging fundamental research with clinical applications. Dr. Khan’s academic influence and research productivity are reflected in his metrics 1,355 citations, 54 documents, and an h-index of 21.

Profiles: Scopus

Featured Publications

Khan, S., et al. (2025). Implication of Toll-Like Receptors in growth and management of health and diseases: Special focus as a promising druggable target to Prostate Cancer. [Review]. 7 citations.

Khan, S., et al. (2025). The implication of microbiome in lungs cancer: mechanisms and strategies of cancer growth, diagnosis and therapy. [Review]. 6 citations.

Khan, S., et al. (2025). Analysis of anti-cancer and anti-inflammatory activity in Typhonium flagelliforme rhizome extract by induction of apoptosis: An in-vitro study. Fitoterapia.

Hifzur R Siddique | Cancer Science | Editorial Board Member

Published on by Oncology

Assist. Prof. Dr. Hifzur R Siddique | Cancer Science | Editorial Board Member

Assistant Professor | Aligarh Muslim University | India

Dr. Hifzur R. Siddique is a distinguished researcher and academic at Aligarh Muslim University, India, specializing in cancer biology, nanomedicine, stem cell research, chemoresistance mechanisms, and translational therapeutics. His work spans the synthesis and characterization of metal oxide nanoparticles with anticancer potential, epigenetic regulation in cancer, and preclinical evaluation of natural compounds like lupeol for chemotherapeutic applications. Dr. Siddique has contributed significantly to methodological advancements, including the use of Drosophila melanogaster models for DNA damage studies and luciferase-based reporter assays for kinase activity assessment. With a robust portfolio of 103 publications in high-impact journals, book chapters, and systematic reviews, he collaborates extensively with over 340 co-authors worldwide, reflecting his leadership in multidisciplinary cancer research. His studies not only advance fundamental understanding of tumor biology but also address translational challenges, bridging laboratory findings to clinical and societal impact. Dr. Siddique’s research has influenced global guidelines on rare malignancies such as NUT carcinoma and contributed to the development of nanocomposite-based therapeutic strategies. His work embodies a commitment to improving cancer outcomes, fostering innovation, and mentoring the next generation of scientists in oncology and biomedical sciences. Dr. Siddique’s academic influence and research productivity are reflected in his metrics 3,083 citations, 103 documents, and an h-index of 30.

Profiles: Google Scholar | Scopus | ORCID | LinkedIn

Featured Publications

Siddique, H. R., & Saleem, M. (2011). Beneficial health effects of lupeol triterpene: A review of preclinical studies. Life Sciences, 88(7-8), 285–293. [Cited by 477]

Siddique, H. R., & Saleem, M. (2012). Role of BMI1, a stem cell factor, in cancer recurrence and chemoresistance: Preclinical and clinical evidences. Stem Cells, 30(3), 372–378. [Cited by 419]

Mishra, S. K., Siddique, H. R., & Saleem, M. (2012). S100A4 calcium-binding protein is key player in tumor progression and metastasis: Preclinical and clinical evidence. Cancer and Metastasis Reviews, 31(1), 163–172. [Cited by 212]

Siddique, H. R., Chowdhuri, D. K., Saxena, D. K., & Dhawan, A. (2005). Validation of Drosophila melanogaster as an in vivo model for genotoxicity assessment using modified alkaline Comet assay. Mutagenesis, 20(4), 285–290. [Cited by 146]

Fatma, H., Maurya, S. K., & Siddique, H. R. (2022). Epigenetic modifications of c-MYC: Role in cancer cell reprogramming, progression and chemoresistance. Seminars in Cancer Biology, 83, 166–176. [Cited by 136]

Jun Lu | Cancer | Editorial Board Member

Published on by Oncology

Prof. Jun Lu | Cancer | Editorial Board Member

Professor | Chengdu University of Traditional Chinese Medicine | China

Dr. Jun Lu is a distinguished researcher at Chengdu University of Traditional Chinese Medicine, China, specializing in cancer nanomedicine, biomaterials, and translational therapeutics. His work focuses on the design and development of multifunctional nanoplatforms, including engineered chitosan nanoparticles, aptamer-conjugated chemotherapeutics, and self-gelling biomaterials for applications in tumor therapy, wound healing, and infectious disease management. Dr. Lu integrates molecular biology, materials science, and bioengineering to advance innovative therapeutic strategies, such as modulating tumor microenvironments, orchestrating DNA damage pathways in colorectal carcinoma, and promoting MRSA-infected wound healing. He has authored 78 publications in high-impact journals including Journal of Translational Medicine, Chemical Engineering Journal, Carbohydrate Polymers, and Nano Research, reflecting strong expertise in nanobiotechnology and translational oncology. His extensive collaborations with over 380 co-authors worldwide demonstrate his leadership in multidisciplinary research networks, bridging fundamental science with clinical applications. Beyond academic contributions, Dr. Lu’s work has significant societal impact by enabling advanced therapies for cancer, infectious diseases, and tissue repair, providing novel solutions to global health challenges. His research emphasizes translational relevance and real-world applicability, contributing to safer, more effective, and innovative therapeutic modalities. Dr. Lu’s academic influence and research productivity are reflected in his metrics 2,421 citations, 78 documents, and an h-index of 24.

Profiles: Google Scholar | Scopus | ORCID 

Featured Publications

Lu, J., Zhang, H., Hou, J., Li, X., Hu, X., Hu, Y., Easton, C. D., Li, Q., Sun, C., … (2020). Efficient metal ion sieving in rectifying subnanochannels enabled by metal–organic frameworks. Nature Materials, 19(7), 767–774. Cited by: 495

Ni, S., Yao, H., Wang, L., Lu, J., Jiang, F., Lu, A., Zhang, G. (2017). Chemical modifications of nucleic acid aptamers for therapeutic purposes. International Journal of Molecular Sciences, 18(8), 1683. Cited by: 384

Lu, J., Jiang, F., Lu, A., Zhang, G. (2016). Linkers having a crucial role in antibody–drug conjugates. International Journal of Molecular Sciences, 17(4), 561. Cited by: 352

Tan, C. M., Therien, A. G., Lu, J., Lee, S. H., Caron, A., Gill, C. J., Lebeau-Jacob, C., … (2012). Restoring Methicillin-Resistant Staphylococcus aureus susceptibility to β-lactam antibiotics. Science Translational Medicine, 4(126), 126ra35.
Cited by: 328

Li, F., Lu, J., Liu, J., Liang, C., Wang, M., Wang, L., Li, D., Yao, H., Zhang, Q., Wen, J., … (2017). A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer. Nature Communications, 8(1), 1390.
Cited by: 275

 

Farhad Vahid | Breast Cancer | Editorial Board Member

Published on by Oncology

Dr. Farhad Vahid | Breast Cancer | Editorial Board Member

Assistance Professor | Luxembourg Institute of Health | Luxembourg

Dr. Farhad Vahid is a prominent researcher at the Luxembourg Institute of Health, Strassen, specializing in nutritional epidemiology, diet-related cardiometabolic health, and public health interventions. His research focuses on understanding the impact of dietary patterns, inflammatory indices, antioxidants, and nutrient intake on chronic diseases, including cardiovascular risk, obesity, breast cancer, and reproductive health. Dr. Vahid has contributed to advancing population-based and clinical research through large cohort studies, randomized clinical trials, and systematic reviews, providing evidence for the development of diet quality indices and population health guidelines. His work emphasizes the intersection of nutrition, chronic disease prevention, and healthy aging, with translational implications for both individual and public health outcomes. Over his career, he has demonstrated strong collaborative engagement, working with multidisciplinary teams across international institutions to address global health challenges through diet and lifestyle interventions. Dr. Vahid’s publications, including studies on dietary carotenoids, the dietary inflammatory index, cardiovascular risk factors, and healthy aging, have informed both scientific understanding and practical public health strategies. His research not only contributes to academic knowledge but also has significant societal impact by guiding nutritional recommendations and interventions aimed at reducing chronic disease burden and promoting population health. Dr. Vahid’s academic influence and research productivity are reflected in his metrics 1,529 citations, 100 documents, and an h-index of 22.

Profiles: Google Scholar | Scopus | ORCID | ResearchGate | LinkedIn

Featured Publications

Vahid, F., Zand, H., Nosrat–Mirshekarlou, E., Najafi, R., & Hekmatdoost, A. (2015). The role dietary of bioactive compounds on the regulation of histone acetylases and deacetylases: A review. Gene, 562(1), 8–15. Cited by 237.

Vahid, F., Shivappa, N., Hekmatdoost, A., Hebert, J. R., Davoodi, S. H., & Sadeghi, M. (2017). Association between maternal dietary inflammatory index (DII) and abortion in Iranian women and validation of DII with serum concentration of inflammatory factors: Case-control study. Applied Physiology, Nutrition, and Metabolism, 42(5), 511–516. Cited by 110.

Ashkar, F., Rezaei, S., Salahshoornezhad, S., Vahid, F., Gholamalizadeh, M., & [others]. (2020). The role of medicinal herbs in treatment of insulin resistance in patients with polycystic ovary syndrome: A literature review. Biomolecular Concepts, 11(1), 57–75. Cited by 96.

Vahid, F., Shivappa, N., Faghfoori, Z., Khodabakhshi, A., Zayeri, F., & Hebert, J. R. (2018). Validation of a dietary inflammatory index (DII) and association with risk of gastric cancer: A case-control study. Asian Pacific Journal of Cancer Prevention: APJCP, 19(6), 1471. Cited by 92.

Vahid, F., Shivappa, N., Karamati, M., Naeini, A. J., Hebert, J. R., & Davoodi, S. H. (2017). Association between dietary inflammatory index (DII) and risk of prediabetes: A case-control study. Applied Physiology, Nutrition, and Metabolism, 42(4), 399–404. Cited by 85.

Sheeba Irshad | Tumour Immunology | Editorial Board Member

Published on by Oncology

Dr. Sheeba Irshad | Tumour Immunology | Editorial Board Member

Senior Clinical Lecturer | King’s College London | United Kingdom

Dr. Sheeba Irshad is a distinguished clinician-scientist at Guy’s Hospital, London, specializing in translational oncology, tumor immunology, and precision medicine, with a strong focus on breast cancer, immune surveillance, therapeutic resistance, oncolytic viro-immunotherapy, and treatment-related toxicities. Her pioneering work advances immune-based therapeutic innovation through Fc-engineered antibodies, viral vaccine–driven T-cell activation, immunomodulatory gene therapies, and strategies aimed at reversing T-cell exhaustion in poorly immunogenic tumors. She has authored 61 publications in leading journals such as Cancer Research, Molecular Therapy, Translational Oncology, and PLOS ONE, addressing critical challenges including breast cancer cardiotoxicity, radiation-induced fibrosis, and the complex interplay between viral immunity and tumor control. Dr. Irshad’s extensive global collaborations—spanning more than 1,300 co-authors—demonstrate her leadership within multidisciplinary cancer research networks and her commitment to integrating molecular biology, immunology, and clinical oncology to accelerate therapeutic translation. Her contributions have significantly influenced the development of safer and more effective immunotherapies, improving patient outcomes and shaping modern oncology practice worldwide. Dr. Irshad’s academic influence and research productivity are reflected in her metrics 2,293 citations, 61 documents, and an h-index of 22.

Profiles: Scopus| ORCID | LinkedIn

Featured Publications

Cheung, A., Chenoweth, A. M., Johansson, A., Laddach, R., Guppy, N., Trendell, J., Esapa, B., Mavousian, A., Navarro-Llinas, B., Haider, S., et al. (2024). Anti-EGFR antibody-drug conjugate carrying an inhibitor targeting CDK restricts triple-negative breast cancer growth. Clinical Cancer Research.

Hsu, R., Al-Zubeidy, B., Flores, D., Nazarian, A., Baugh, A., Gonzalez, E., Castanon, S., Xiu, J., Kang, I., Spicer, D., et al. (2024). Evaluation of markers of immunity in different metastatic immune microenvironments suggests more suppression within breast-to-liver metastases in breast cancer. Breast Cancer Research and Treatment.

Jahangir, C. A., Page, D. B., Broeckx, G., Gonzalez, C. A., Burke, C., Murphy, C., Reis-Filho, J. S., Ly, A., Harms, P. W., Gupta, R. R., et al. (2024). Image-based multiplex immune profiling of cancer tissues: Translational implications. Report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. The Journal of Pathology.

Tang, C. C., Timbres, J., Ramsey, K., Mera, A., Irshad, S., Sawyer, E., & Khan, A. (2023). Clinico-pathological co-variates define a predictive model of breast cancer-related lymphoedema (BCRL) in patients undergoing axillary surgery for breast cancer. Cancer Research.

Fatayer, H., O’Connell, R. L., Bannon, F., Coles, C. E., Copson, E., Cutress, R. I., Dave, R. V., Gardiner, M. D., Grayson, M., Holcombe, C., et al. (2023). Current practice and surgical outcomes of neoadjuvant chemotherapy for early breast cancer: UK NeST study (Vol. 109, p. 800, 2022). BJS.